ＣＤ４０に対する抗体

Japanese Patent JP5848232

B2

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

Bedian Buffet
Graduone Ronald Pee.
Corbalan Jose
Ja Xiao
Feng Xiao

JP2012270885A

January 27, 2016

December 12, 2012

Click for automatic bibliography generation  

Pfizer Products Inc.
Amgen Fremont Ink.

A01H5/00; A01H1/00; C12N15/09; A01K67/027; A61K31/7088; A61K35/76; A61K39/395; A61K48/00; A61P13/08; A61P13/10; A61P35/00; A61P35/02; A61P43/00; C07K16/28; C07K16/40; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/07; C12N5/078; C12N5/09; C12N5/10; C12N15/02; C12N15/12; C12P21/02; C12P21/08; C07K

WO2001083755A1
WO1995017202A1

Cancer Res.,2000年,vol. 60,3225-3231
J. Immunol. Methods,2001年 2月,vol. 248,139-147
Eur. J. Immunol.,1994年,vol. 24,1835-1842
Hybridoma,1999年,vol. 18,471-478
Hybridoma,1997年,vol. 16,217-226

Hatsushi Shimizu
Toshi Gobe
Koichi Niimi
Kazuya Kawamoto

Previous Patent: 車両遠隔操作システム

Next Patent: JPS5848233